The effects of air pollution on heart health are well known now, and it can be an issue for people in both urban and rural areas of the United States, explained Jeanette Stingone, PhD, of Mount Sinai Health System.
The effects of air pollution on heart health are well known now, and it can be an issue for people in both urban and rural areas of the United States, explained Jeanette Stingone, PhD, of Mount Sinai Health System.
Transcript (slightly modified)
What are the basic effects of air pollution on cardiovascular health?
We’ve known that air pollution affects health in general for centuries. It was probably the Six Cities Study in the early 1990s that really established that air pollution was associated with a greater morbidity and mortality. Since then, they really start to look at what are the mechanisms for that relationship that they observed, and it’s vast. We have seen associations between exposure to air pollution and heart rate variability, and mean heart rate, thrombus formation, atherosclerosis, and all of those things contribute to cardiovascular outcomes later in life.
Are there notable locations in the United States where we see a connection between air pollution and heart health?
Pretty much wherever people look. When they see higher level of air pollution they see associations with cardiovascular outcomes. So, from big cities like New York and Los Angeles, to even rural areas that may be near an industrial site. So, it’s not like if you don’t live in LA you’re safe—it’s really a problem everywhere and it’s something to consider no matter where you live.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More